Literature DB >> 2618755

Appearance and persistence of 11 beta-hydroxypregna-1,4-diene-3,20-dione (delta HOP) effect "in vivo".

C M Rondinone1, R Schillaci, C P Lantos, A Roldán.   

Abstract

The effect "in vivo" of 11 beta-hydroxy-pregna-1,4-diene-3,20-dione (delta HOP) in acute and chronic treatment was studied in mice compared to those treated with dexamethasone and vehicle. In acute experiments an injection of 2 mg/100 g body weight of delta HOP had a maximal inhibitory effect in 3H-uridine incorporation by thymocytes 18 h after the injection, disappearing 36 h later, meanwhile no change was observed in plasma corticosterone levels at any time. The dose 0.033 mg/100 g body weight of dexamethasone produced a high inhibition 5 h after the injection, and a significant decrease in plasma corticosterone was produced at this time; the effect disappeared at 24 h. In the chronic treatment delta HOP produced the maximal inhibition 5 h after the treatment; this effect was maintained until 36 h and disappeared at 48 h without change in corticosterone levels. Meanwhile dexamethasone produced the same inhibition as delta HOP 5 h after the treatment; this effect disappeared after 18 h. In those animals plasma corticosterone decreased during longer time than in acute treatment, since it continued lower than normal at 18 h and it recovered at 24 h. After 5 h of a chronic treatment delta HOP did not change thymus and spleen weights, but they decreased with dexamethasone treatment. These results suggest that the "in vivo" actions of delta HOP is different from that of glucocorticoids.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2618755

Source DB:  PubMed          Journal:  Acta Physiol Pharmacol Latinoam        ISSN: 0326-6656


  1 in total

1.  Inhibitory effect of 11 beta-hydroxypregna-1,4-diene-3,20-dione (delta HOP) on lymphocyte proliferation.

Authors:  C M Rondinone; R Schillaci; M B Castillo; A Roldán
Journal:  Clin Exp Immunol       Date:  1991-11       Impact factor: 4.330

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.